Skip to main content
Contact Us
Subscribe
E-Edition
75°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
393.89
+0.41 (+0.10%)
Streaming Delayed Price
Updated: 3:41 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 11, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
December 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Appoints Nancy Thornberry to its Board of Directors
December 05, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
November 23, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
InvestorNewsBreaks – Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Featured in Barron’s Article for Potential Near ‘Breakthrough’
November 16, 2023
Via
Investor Brand Network
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
November 16, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
MarketBeat Week in Review – 11/6 - 11/10
November 11, 2023
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Why you can make Vertex Pharmaceuticals a buy on any pullback
November 08, 2023
Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely
Via
MarketBeat
Exposures
COVID-19
Vertex Reports Third Quarter 2023 Financial Results
November 06, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
November 02, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present at Upcoming Investor Conferences
October 26, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Tuesday Session
October 17, 2023
Via
Investor Brand Network
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Friday Session
October 13, 2023
Via
Investor Brand Network
Vertex to Announce Third Quarter 2023 Financial Results on November 6
October 10, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Appoints Michel Lagarde to its Board of Directors
October 05, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
October 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
September 15, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
September 14, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
August 30, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
August 29, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Strong Biotech Performers To Watch As Sector Nears Breakout
August 17, 2023
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming.
Via
MarketBeat
Topics
ETFs
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
August 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Second Quarter 2023 Financial Results
August 01, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Biotech Stocks to Buy for Long-Term Gains
July 13, 2023
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Vertex to Announce Second Quarter 2023 Financial Results on August 1
June 30, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
June 30, 2023
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June.
Via
MarketBeat
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
June 26, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
June 23, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Is the Biotech Industry (IBB) Poised For A Major Breakout?
June 12, 2023
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range.
Via
MarketBeat
Topics
ETFs
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.